The Expertise Imperative and Compliance Technology
Access to a diverse array of specialized expert inputs drives superior decisions in every organizational context: within corporations, by investors and consultancies, and within nonprofits. When decision makers are confident of their decision inputs, they can respond more quickly and creatively to challenges and opportunities.Learn more about GLG's Compliance Framework
This page may include content provided by Council Members, your access to which is subject to the Terms of Use.
The info that tekturna HCT works twice as well as HCTZ alone is not earth shattering. Of course it's better. That can be said of any HCT/medicine combination
I am a heavy user of ARB's and Tekturna. This article does not really show anything of significance. Most practicing physicians have seen much better results and much better tolerability with ARB's than diuretics. I do not think this is going to change prescribing habits of anyone. ...
Mechanical thrombectomy of the coronary arteries has becoming increasingly more common with the advent of simpler aspiration catheters. Although its use in the setting of acute myocardial infarction is even more common, it is not routine. Randomized data indicating its effect on clinical...
This is not a real life article. Physicians will titrate the dosage of beta blockers, not utilize a fixed dose. The AHA ACC guidelines still recommend beta blockers, but the guidelines do not specifiy a fixed dosage.
Acute myocardial infarction is caused by a clot in the artery that obstructs and quickly reduces blood flow to the artery. The best treatment for STEMI is rapid opening of the artery with angioplasty and stenting. The article is important since it shows that active removal of the clot prior to stenting...
Novartis was able to show that combining tekturna with HCTZ provided significant improvement in blood pressure and did so safely. They also showed that it provides better 24 hour coverage and coverage if patients miss a dose or take it late, this is a significant improvement over its competitors...
It is well known that the addition of thiazide diuretic to ACEI or ARB treatment adds about 10 mm Hg reduction on top of the 10 mm Hg reduction provided by the ACEI or ARB agent. It is expected that blocking renin in the renin angiotensin system with Tekturna would provide a similar result.
Study will be ridiculed. 1) Comparator drug is not appropriate. 2) Not an outcomes study. 3) Time frame too short to be clinically significant. 4) Drug too expensive for first line use. 5) Long term safety not established.
Immunomodulation especially with antibodies is difficult. Proteins are not as easily given and distributed through the body as low molecular weight compounds. I believe that the first drug to be effective will pave the way for many others